Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
Status:
Completed
Trial end date:
2018-07-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
maximum tolerated dose (MTD) of YYB101, HGF-neutralizing humanized Mab, in advanced solid
tumors patients who are refractory to standard therapy.